MLF-541

MLF-541 is an investigational pharmaceutical formulation consisting of parenteral fish oil highly enriched in omega-3 fatty acids, specifically eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). It has been studied for its safety and effects in organ donors and kidney transplant recipients. The drug is designed to deliver high concentrations of omega-3 fatty acids intravenously, with the aim of modulating inflammation and improving outcomes in transplantation settings. The mechanism of action is believed to involve anti-inflammatory effects mediated by omega-3 fatty acids, which may help reduce cytokine release and improve organ function post-transplantation. Further studies are needed to establish its efficacy as a pharmacological agent in this context[1][2].